One should be considered for post-exposure anti-influenza chemoprophylaxis when:
- The illness seen shortly after the influenza vaccination.
- People who vaccine is contraindicated (including anaphylaxis to egg)
- History of Guillain-Barre Syndrome within weeks of previously admnistered vaccine
- Unvaccinated in close contact with those high risk of developing influenza complications
- All residents of long term facilities ot nursing home, including those already vaccinated.
- Immunocompromised people
- People who were unable to get vaccine due to shortage, if the person is at high risk of developing complication of influenza.
Oselatmivir PO:
a. 3 months to < 1 y/o: 3 mg/kg OD
b. > 1 y/o and BW < 15kg: 30mg OD
c. 15 - 23 kg: 45mg OD
d. 23 - 40 kg: 60mg OD
e. > 40kg and adults: 75mg OD
Reference: BMJ Best Practice
Comments